Until law, GLP-1 drugs were used to treat diabetes, obesity and even the recent evidences suggest that it could as well be used to treat chronic kidney problems. There is yet another research, published in JAMA Psychiatry on February 25, titled Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial that explores if GLP-1 receptor agonist semaglutide reduce alcohol consumption and cravings in adults with alcohol use disorder.

What Do Studies Say?

The research was conducted over a period of 9 weeks, where in the randomized clinical trial, the participants who were administered semaglutide, it led to reductions in some but not all measures of weekly consumptions. It also reduced weekly alcohol and craving related to placebo, and also led to a greater relative reduction in cigarettes per day.

The research also found that weekly injections of semaglutide, which is the active ingredient in weight loss drugs like Wegovy also helped reduce cravings in people with alcohol use disorder.

The lead author Christian Hendershot said that these findings will help in developing new approaches to treat alcoholism. "Two drugs currently approved to reduce alcohol consumption aren't widely used. The popularity of Ozempic and other GLP-1 receptor agonists increases the chances of broad adoption of these treatments for alcohol use disorder," said Hendershot in news release by the University of Southern California's Institute for Addiction Research, where he is the director.

The study is government-funded research and was funded by the National Institute on Alcohol Abuse and Alcoholism, part of the National Institutes of Health.

How Was The Study Conducted?

The study was small, and took in account for only 48 adults over two months, thus experts say that it is not yet clear how safe these drugs are for people who do not need to lose weight. Though the results do add up with the evidence form animal studies on drugs like Ozempic and Wegovy on how it helps manage cravings, not just for food, but also for tobacco and alcohol. Scientists are also studying these drugs on smokers, people with opioid addiction and cocaine users.

Co-author Dr Klara Klein of the University of North Carolina at Chapel Hill who treats people with obesity and diabetes said, "This is such promising data. And we need more of it. We frequently will hear that once people start these medications that their desire to drink is very reduced, if not completely abolished."

Why Does It Work So Well Against Alcoholism?

The GLP-1 receptor agonists work by mimicking hormones GLP-1 in the gut and brain that regulates appetite and feelings of fullness. This response is what helps one lose weight, and what helps one curb their craving for alcohol. These drugs that mimic the functioning of your brain, which is responsible to tell your body when to stop consuming, are the same hormones that tell your body about other kinds of consumptions, including alcohol. Therefore by consuming the weight loss drugs one can treat alcohol use disorder.

However, the researchers have pointed out on the limited data on the research and have suggested to continue using the three approved drugs by the National Institute on Alcohol Abuse and Alcoholism and Substance Abuse and Mental Health Services Administration, namely, Disulfiram, Naltrexone, and Acamprosate to treat alcohol use disorder until large studies confirm these findings.

Nearly 4 in 10 US high school students reported binge eating at least once in the previous 30 days in 2025, according to a new survey by the US Centers for Disease Control and Prevention (CDC).

The biennial Youth Risk Behavior Survey found that 40.5% of students reported binge eating on at least one day, while 17.2% reported it on three or more days. Frequent binge eating was more common among female students (18.6%) than male students (15.9%).

Binge Eating Linked to Poor Mental Health

The survey was conducted among 10,710 students in grades 9–12. However, valid responses to the binge-eating question were available for 6,898 students.

Students reporting poor mental health were more likely to report binge eating on three or more days in the previous 30 days than those who did not report poor mental health (27.2% versus 14%).

The prevalence was also higher among students reporting persistent sadness or hopelessness (25.4% versus 12.8%) and those who had seriously considered attempting suicide (27.1% versus 15.3%).

Previous research has linked binge eating with depression, anxiety, suicidal ideation and suicide attempts. However, the CDC noted that its cross-sectional findings cannot establish cause and effect or determine which condition came first.

“It was extremely alarming seeing how high those numbers were,” Ariel Beccia, a researcher in the adolescent and children’s medicine division at Boston Children’s Hospital, told STAT News.

“Eating disorders not only affect everyone, they also affect marginalized youth more, actually,” Beccia said.

Frequent Social Media Use Also Linked to Binge Eating

Students who used social media at least hourly were more likely to report binge eating on three or more days than those who used it once a day or less (22.8% versus 12.9%).

Exposure to appearance- and diet-related content, comparisons with others and idealized body standards have been proposed as possible pathways linking social media use to body dissatisfaction and binge eating. However, the survey measured how frequently students used social media, not the content they viewed, and cannot establish that social media use causes binge eating.

Differences Across Student Groups

Frequent binge eating was reported by 20.5% of Hispanic students and 18.7% of Black students, compared with 14.6% of White students. The prevalence was 19.6% among multiracial students and 9.9% among Middle Eastern or North African students.

The CDC cautioned that the estimate for Middle Eastern or North African students was imprecise because of the small sample size. These figures refer to binge eating on three or more days in the previous 30 days.

The findings highlight the need for continued monitoring of disordered eating among adolescents, along with prevention, early identification and access to appropriate support. The CDC said schools, families, health care providers and mental health professionals could play a role in these efforts.

What Is Binge Eating?

Binge eating involves consuming an unusually large amount of food in a short period while feeling a loss of control over eating. It is a form of disordered eating, but it does not necessarily meet the criteria for a diagnosis of binge-eating disorder.

Signs and symptoms of binge-eating disorder may include:

• Eating until uncomfortably full
• Eating more quickly than usual
• Eating despite not feeling hungry
• Turning to food during stress or emotional distress
• Eating alone out of embarrassment
• Experiencing guilt, shame or a sense of losing control over eating

How Is Binge Eating Treated?

Treatment may include psychotherapy (talk therapy), such as cognitive behavioral therapy (CBT) and interpersonal psychotherapy (IPT). Depending on individual needs, treatment may also involve medication and nutritional counseling.

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has introduced new measures to improve how the risks of suicidal thoughts and behaviors and persistent sexual dysfunction are communicated to people taking antidepressants.

Following a review involving patients and their families, the MHRA will introduce a boxed warning in patient information leaflets (PILs), a patient safety card, and an additional safety leaflet. The term “post-SSRI sexual dysfunction” (PSSD) will also be added to the leaflets for certain antidepressants.

“Patients need clear and accessible information about the benefits and risks of medicines so they can make informed decisions,” Dr. Alison Cave, MHRA chief safety officer, said.

She said the changes would support informed discussions among patients, caregivers, and healthcare professionals. Dr. Cave added that antidepressants can effectively treat depression when used appropriately and under clinical supervision. Patients should not stop taking these medicines without first consulting their healthcare professional.

What Are the New Antidepressant Warnings?

Also read: GLP-1 Drugs May Offer Mental Health Benefits, Reduce Schizophrenia Relapses: Lancet Study

Patient information leaflets will feature a boxed warning directing readers to information about suicidal thoughts and behaviors, making the guidance easier to find.

A patient safety card is expected to accompany medicine packaging, reinforcing key safety messages and explaining when and how to seek support.

For certain antidepressants, updated leaflets will include information on PSSD, highlighting the possibility that sexual dysfunction may persist after treatment ends.

The MHRA is also developing an additional safety leaflet with the wider healthcare system. Expected in 2027, it will explain the benefits and risks of antidepressant treatment to support informed decisions. It will be given to patients at their first appointment discussing antidepressants and to those already receiving treatment.

Concerns Over SSRI Safety Warnings

The MHRA has received four prevention of future deaths reports since 2020 concerning antidepressant prescribing and safety information. One followed the 2024 death by suicide of Thomas Kingston, husband of Lady Gabriella Kingston, at age 45.

An inquest heard that Kingston had been prescribed sertraline and later switched to citalopram after reporting that his medication was not helping. Both are selective serotonin reuptake inhibitors (SSRIs). He had also received the sleeping tablet zopiclone for sleep difficulties and had stopped taking his medication before his death.

Gloucestershire senior coroner Katy Skerrett questioned whether patients were adequately informed about the suicide risks associated with SSRIs. Kingston’s parents called for clearer communication of potential side effects to patients and their families.

Read More: AI Chatbots May Be Changing How Children Seek Emotional Support

What Should Healthcare Professionals Do?

The MHRA advises healthcare professionals to:

• Discuss the risk of suicidal thoughts and behaviors when starting antidepressants, changing doses, and during subsequent reviews.
• Explain that some antidepressants can cause sexual dysfunction that may continue after treatment stops.
• Follow relevant National Institute for Health and Care Excellence (NICE) guidance and monitor patients regularly after treatment begins.
• Provide the additional safety leaflet when it becomes available in 2027.
• Report suspected adverse reactions through the MHRA’s Yellow Card scheme.

What Should Patients Taking Antidepressants Know?

Patients experiencing new or worsening suicidal thoughts should seek urgent medical attention, particularly when starting treatment or changing their dose. In the UK, they can contact NHS 111, their local mental health crisis team, Samaritans on 116 123, or the SHOUT text service at 85258.

Anyone concerned about sexual dysfunction during or after antidepressant treatment should contact their healthcare professional.

The MHRA said these are not new risks associated with the medicines. Patients should read the information supplied with their medication and consult their healthcare professional before stopping treatment.

Lead poisoning is a widespread but preventable health threat that contributes to more than 3.5 million deaths globally each year and puts hundreds of millions of children at risk, the World Health Organization (WHO) said.

Marking International Lead Poisoning Prevention Week 2026, WHO urged countries to accelerate prevention efforts amid growing global momentum to tackle lead exposure.

Why Is Lead Dangerous for Children?

Also read: Lead Found In Everyday Vegetables - Reveals A Bengaluru Study

Children are particularly vulnerable to lead because their developing brains and nervous systems are highly susceptible to its toxic effects. Even low levels of exposure can cause irreversible harm, affecting learning, behavior and development.

“Lead poisoning should not be stealing children's potential in 2026,” said Bruce Gordon, Director a.i. of WHO’s Department of Environment, Climate Change, One Health and Migration.

“We know where many exposures come from and we know how to prevent them. Countries now need to move upstream, removing lead from products and environments before it reaches a child's bloodstream. WHO is working with governments and partners to help turn that evidence into action,” Gordon added.

How Does Lead Poisoning Occur?

There is no known safe level of lead exposure, WHO warned. Exposure can occur through paint, cookware, cosmetics, spices, informal recycling and industrial contamination, among other sources.

Lead affects multiple organs and can contribute to cardiovascular and kidney disease in adults. In children, exposure can cause lasting damage to brain function and development. Its effects may go undetected until significant harm has occurred.

Lead is distributed to the brain, liver, kidney and bones. It is stored in the teeth and bones, where it can accumulate over time. Human exposure is assessed through the measurement of lead in blood.

WHO Plans Global Action On Lead Exposure

Fewer than half of countries had confirmed legally binding controls on lead paint, according to WHO's latest published global assessment.

This year's International Lead Poisoning Prevention Week theme, “From Detection to Prevention,” highlights the need for stronger policies, better enforcement of safety standards and greater public awareness to eliminate lead hazards at their source.

WHO Member States have recognized lead exposure as a pressing public health concern and mandated the development of a Global Action Plan on Lead Mitigation, which will be presented to the World Health Assembly in 2027.

The WHO will also launch the PREVENT Technical Package on Lead Poisoning Prevention in 2027. It will provide practical guidance to help countries identify major exposure sources, prioritize interventions, strengthen regulations and track progress.

Last year, WHO joined partners in the Lead Poisoning Prevention Initiative to strengthen laboratory capacity for blood lead testing, supporting the monitoring and early detection of exposure.

The initiative will provide technical support and build laboratory capacity in Brazil, five states in India, Nepal and six sub-Saharan African countries: Ethiopia, Ghana, Malawi, Rwanda, South Africa and the United Republic of Tanzania.

WHO Calls for Stronger Prevention Measures

Preventing lead exposure can also reduce health care costs, improve educational outcomes and support healthier, more productive societies.

The WHO urged countries to move beyond detecting lead exposure and adopt comprehensive prevention strategies such as:

• Eliminating lead hazards from products and environments.
• Strengthening regulations and enforcement.
• Improving monitoring and surveillance of lead exposure.
• Strengthening capacity to manage lead poisoning cases.
• Raising public awareness about exposure sources and prevention.
• Promoting safer industrial practices and waste management.
• Prioritizing children and other vulnerable populations.